VMD vs. ARA, CO, CORBF, OTRK, MGRX, BRTX, MRAI, GBNHF, TVTY, and PGNY
Should you be buying Viemed Healthcare stock or one of its competitors? The main competitors of Viemed Healthcare include American Renal Associates (ARA), Global Cord Blood (CO), Global Cord Blood (CORBF), Ontrak (OTRK), Mangoceuticals (MGRX), BioRestorative Therapies (BRTX), Marpai (MRAI), Greenbrook TMS (GBNHF), Tivity Health (TVTY), and Progyny (PGNY).
American Renal Associates (NYSE:ARA) and Viemed Healthcare (NASDAQ:VMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, community ranking, valuation, risk and analyst recommendations.
Viemed Healthcare has lower revenue, but higher earnings than American Renal Associates. Viemed Healthcare is trading at a lower price-to-earnings ratio than American Renal Associates, indicating that it is currently the more affordable of the two stocks.
In the previous week, Viemed Healthcare had 2 more articles in the media than American Renal Associates. MarketBeat recorded 2 mentions for Viemed Healthcare and 0 mentions for American Renal Associates. American Renal Associates' average media sentiment score of 1.88 beat Viemed Healthcare's score of 0.00 indicating that Viemed Healthcare is being referred to more favorably in the news media.
Viemed Healthcare has a net margin of 5.32% compared to Viemed Healthcare's net margin of -2.04%. American Renal Associates' return on equity of 9.32% beat Viemed Healthcare's return on equity.
American Renal Associates received 204 more outperform votes than Viemed Healthcare when rated by MarketBeat users. Likewise, 62.73% of users gave American Renal Associates an outperform vote while only 42.86% of users gave Viemed Healthcare an outperform vote.
78.4% of American Renal Associates shares are held by institutional investors. Comparatively, 74.2% of Viemed Healthcare shares are held by institutional investors. 9.5% of American Renal Associates shares are held by company insiders. Comparatively, 20.0% of Viemed Healthcare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
American Renal Associates has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Viemed Healthcare has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500.
Summary
Viemed Healthcare beats American Renal Associates on 11 of the 16 factors compared between the two stocks.
Get Viemed Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for VMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viemed Healthcare Competitors List
Related Companies and Tools
